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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) has been used to treat several forms of leukemia
and has been particularly effective in increasing the survival
rates of patients with acute myelogenous leukemia and
chronic myelogenous leukemia [1,2]. Two inversely related
complications, however, graft-versus-host disease (GVHD)
and leukemic relapse, have high impact on the morbidity
and mortality rates following HSCT [3-8]. A positive clini-
cal outcome largely depends on balancing the negative
effects of GVHD and the positive effects of graft-versus-
leukemia (GVL) activity of donor T cells. When T cells are
depleted from stem cell allografts, there is a marked reduc-
tion in GVHD but there is an increased incidence of
leukemic relapse [3-8]. Donor T cells are recognized as the
only means of avoiding leukemic relapse in chronic myel-
ogenous leukemia [9], and delayed infusion of T cells has
become a standard treatment approach [10-14], although
the success of this treatment is still signiﬁcantly hampered
by the incidence of GVHD. Therefore, a major goal of
donor T-cell therapy is to provide a GVL effect while less-
ening the incidence and severity of GVHD.
Various strategies have been employed to separate
GVHD from GVL activities, including CD4+, CD6+, and
CD8+ T cell–subset depletions [15-17]; in vivo α-CD3
monoclonal antibody (MoAb) administration [18,19]; in
vivo cytokine manipulation [20,21]; ex vivo tolerization of
alloreactive T cells [22,23]; and separation of donor T cells
based on functional phenotypes (cytokine profiles [24] or
cytolytic effector mechansims [25-27]). These approaches,
however, do not take into account the antileukemia speci-
ficity of donor T cells but rely instead upon broad differences
Infusion of Select Leukemia-Reactive TCR Vβ+ T Cells
Provides Graft-Versus-Leukemia Responses With
Minimization of Graft-Versus-Host Disease Following
Murine Hematopoietic Stem Cell Transplantation
Anthony E. Patterson, Robert Korngold
Kimmel Cancer Institute, Jefferson Medical College, Philadelphia, Pennsylvania
Correspondence and reprint requests: Robert Korngold, PhD, Kimmel Cancer Center, Jefferson Medical College, 
233 S 10th St, Philadelphia, PA 19107 (e-mail: R_Korngold@lac.jci.tju.edu).
Received December 11, 2000; accepted January 25, 2001
ABSTRACT
T-cell receptor (TCR) V–expression analysis by complementarity-determining region 3 (CDR3)-size spectratyping
can identify the reactive populations in an immunologic response. This analysis was used in this study to characterize
the V responses of C57BL/6 (B6) CD4+ and CD8+ T cells directed to either alloantigen (against [B6×DBA/2]F1;
anti-H2d) or the syngeneic myeloid leukemia MMB3.19. V families exhibiting reactivity to the leukemia cells were
then enriched for and administered in both syngeneic and allogeneic hematopoietic stem cell transplantation (HSCT)
models to assess in vivo graft-versus-leukemia (GVL) potential. In syngeneic transplants, enrichment for pools of
selected V families (V7, -11, and -13) of T cells or for a single V family (V7) of CD4+ T cells conveyed a benefi-
cial GVL response to the recipients. Furthermore, in the haploidentical allogeneic model, both V6,7-enriched
donor B6 T cells and V7-enriched CD4+ T cells exhibited significant GVL responses with concomitant minimiza-
tion of graft-versus-host disease (GVHD) development compared with equal numbers of unfractionated T cells.
These results suggest that CDR3-size spectratype analysis of and subsequent selection from donor T-cell repertoires
can be an effective approach to separate GVL and GVHD potential following allogeneic HSCT. 
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in activation thresholds or functional effector mechanisms
for a selective antileukemia effect.
An approach that should theoretically allow for a more
specific separation of GVH-reactivity from GVL effects
involves analysis of T-cell receptor (TCR) Vβ chain utiliza-
tion in these responses by complementarity-determining
region 3 (CDR3)-size spectratyping and selective adminis-
tration of those Vβ families demonstrating an antileukemic
response. TCR Vβ CDR3-size spectratyping is a method for
identifying the reactivity of T-cell populations responding
to given antigen challenges [28] such as major histocompati-
bility complex (MHC) or minor histocompatibility alloanti-
gen differences or leukemia-related antigens. This latter cat-
egory would include leukemia-specific antigens such as
bcr-abl [29-31] and overexpressed or aberrantly expressed
normal antigens such as proteinase 3 [32]. It is important to
note that separation on the basis of T-cell reactivity can be
performed without having to deﬁne the antigens being rec-
ognized and would allow for a more speciﬁc administration
of leukemia-reactive T-cell populations.
Vβ CDR3-size spectratyping has been used to identify
alloreactive populations of T cells in murine [33] and human
[28] transplantation systems, and it has been recently
demonstrated that depletion of donor cells based on spec-
tratype skewing can allow for minimization of CD4-mediated
GVHD in an MHC-matched allogeneic murine model [34].
However, the hypothesis that this approach could allow for
a meaningful GVL response with a concurrent GVHD
reduction has yet to be directly supported. To address this
possibility, we analyzed the syngeneic anti–myeloid
leukemia responses for both CD4+ and CD8+ T cells in the
C57BL/6 (B6) anti-MMB3.19 model and the alloreactive
responses in the B6 anti-(B6×DBA/2)F1 (B6D2) strain com-
bination, using Vβ CDR3-size spectratyping. We report
here that infusion of leukemia-reactive Vβ populations of
T cells in either syngeneic or allogeneic bone marrow trans-
plantation (BMT) settings allowed for a signiﬁcant retention
of GVL activity, and, in the allogeneic setting, a concomi-
tant mitigation of GVHD.
MATERIALS AND METHODS
Mice
Male B6 (H2b) and B6D2 (H2b/d) mice were purchased
from the National Cancer Institute Animal Procurement
Program (Frederick, MD). Donor mice were aged 8-10 weeks
and recipients aged 6-10 weeks. Mice were housed in a ster-
ile environment in microisolators and given autoclaved food
and acidiﬁed water ad libitum.
Cell Line and Media
MMB3.19 is a c-myc retrovirus–transformed myeloid
leukemia line of B6 origin that has been previously charac-
terized and does not produce retrovirus particles [17,27,35].
MMB3.19 was grown in RPMI 1640 (Mediatech, Herndon,
VA) plus 10% fetal calf serum (Sigma Chemical, St Louis,
MO) supplemented with L-glutamine, penicillin/strepto-
mycin (Mediatech) and 2-mercaptoethanol (Life Technolo-
gies, Grand Island, NY), at 37°C in 7% CO2. Phosphate
buffered saline (PBS) supplemented with 0.1% bovine serum
albumin (BSA; Sigma) was used for in vitro manipulation of
donor bone marrow cells and lymphocytes. Cells were resus-
pended in PBS alone for all injections into recipients.
Monoclonal Antibodies
Anti-Thy-1.2 (J1j; rat immunoglobulin [Ig]M [36]),
anti-CD8 (3.168; rat IgM [37]), and anti-CD4 (RL172; rat
IgM [38]) MoAbs were obtained from ascites ﬂuid and used
with guinea pig C′ (C′) (Rockland, Boyertown, PA) for cell
depletions (always used at 1:10 dilution). Affinity-purified
goat anti-mouse IgG antibody (Cappel-Organon Teknika,
West Chester, PA) was used for B-cell panning. For pheno-
typic analysis or selection of donor T-cell populations, ﬂuo-
rescein isothiocyanate (FITC)-labeled MoAbs were used,
directed to the following determinants: CD3, CD4, CD8,
B220, Vβ2, -3 -4, -5.1/5.2, -6, -7, -8.1/8.2, -8.3, -9, -11, -12,
-13, and -14 (all from Pharmingen, San Diego, CA).
Preparation of Cells
Anti-Thy-1 MoAb–treated (T cell–depleted) bone mar-
row (ATBM) was prepared by ﬂushing femurs and tibiae of
donor mice and incubating the bone marrow cells with J1j
MoAb (1:200 dilution) and C′ for 45 minutes at 37°C. To
obtain T cell–enriched donor populations, spleen and lymph
node (LN) cells were treated with red-blood-cell lysing solu-
tion (containing 0.8% NH4Cl) and allowed to adhere for
1 hour at room temperature to plastic Petri dishes coated with
a 1:200 dilution of goat anti-mouse IgG (to remove B cells).
The collected nonadherent T cells were further enriched for
either CD4+ (by treatment with anti-CD8 MoAb at 1:100
dilution and C′) or CD8+ T cells (by treatment with anti-
CD4 MoAb at 1:100 dilution and C′) for 45 minutes at 37°C.
Vβ-enriched or depleted T-cell populations were obtained
by magnetic bead separation using the varioMacs system
(Miltenyi Biotec, Bergisch Gladbach, Germany).
Flow Cytometry
For phenotypic analysis of T cell–enriched populations,
appropriate FITC-labeled MoAbs in 25 µL were incubated
with 2 × 105 cells in 96-well round-bottom plates for 30 min-
utes at 4°C and washed 3 times with 100 µL PBS plus 1%
BSA plus 0.02% sodium azide. Samples were then ﬁxed with
1% paraformaldehyde and analyzed for ﬂuorescence on an
EPICS Elite ESP analyzer (Coulter Electronics, Hialeah,
FL) in the Kimmel Cancer Center Flow Cytometry Facility.
Preparation of RNA and Complementary DNA
Alloreactive CD4+ and CD8+ T cells were isolated by
B-cell panning and appropriate MoAb plus C′ treatment (as
described above) from spleens of irradiated (split-dose,
13 Gy) B6D2 recipients 5 days after transplantation of 3 ×
107 B6 T cells. Anti-MMB3.19 CD4+ and CD8+ T cells were
isolated from popliteal LN of B6 mice primed (week –3) and
boosted (week –1) with 2 × 106 irradiated (40 Gy) MMB3.19
cells injected subcutaneously into the footpad. Control B6
CD4+ and CD8+ T cells were obtained from LN of naive B6
mice. Total cellular RNA from these T-cell populations was
generated by homogenation in 0.5 to 1 mL of Ultraspec
(Biotecx Laboratories, Houston, TX), followed by addition
of chloroform (1:5 volume), shaking, incubation on ice for
5 minutes, and centrifugation for 15 minutes at 14,000 rpm.
The aqueous phase was transferred to an Eppendorf tube,
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and RNA was precipitated with isopropanol (1:1 volume) for
10 minutes at 4°C followed by centrifugation for 20 minutes
at 4°C. After washing 2 times with 75% ethanol in diethyl
pyrocarbonate (DEPC) water, the RNA pellet was resus-
pended in 25 µL DEPC water and stored at –20°C. Recov-
ery of RNA was determined by spectrophotometry. Oligo
(dT) was used as a primer for reverse transcription of RNA
to complementary (c) DNA. Total RNA of 2 µg in a volume
of 9.5 µL was heated to 70°C and added to a master mix
(17.5 µL) of 1 µL RNasin (40 U/µL); 6 µL 5× Maloney
murine leukemia virus (MMLV) reverse transcriptase reac-
tion buffer; 6 µL oligo (dT) primer (20 mmol/L); 1.5 µL
deoxynucleotide triphosphates A, G, C, and T (25 mmol/L
each); and 3 µL MMLV reverse transcriptase (300 U/µL),
incubated at 37°C for 1.5 hours followed by a 3-minute incu-
bation at 95°C, and stored at –20°C. All reverse transcriptase
reagents were purchased from Promega (Madison, WI).
Polymerase Chain Reaction Amplification and 
CDR3-Size Spectratyping
Polymerase chain reaction (PCR) of T-cell cDNA sam-
ples was performed using 1.2 µL cDNA (50 ng/µL); 1.5 µL
10× AmpliTaq Gold polymerase buffer; 0.12 µL AmpliTaq
Gold polymerase; 1.5 µL of deoxynucleotide triphosphates
A, G, C, and T (25 mmol/L each); 1.5 µL MgCl2; 5.18 µL
DEPC treated water; and 1 µL each of ﬂuorescence-labeled
β2m antisense primer, unlabeled β2m sense primer, ﬂuores-
cence-labeled constant primer (Cβ), and unlabeled Vβ-speciﬁc
primers for each Vβ family. All primers used have been pre-
viously described [33,39]. All PCR reagents were purchased
from Perkin-Elmer (Emeryville, CA). For the MMB3.19-
presensitized samples, a second PCR reaction was performed
to amplify the signals. The ﬂuorescence-labeled PCR prod-
ucts were then run on a sequencing gel and analyzed on an
automated DNA sequencer using GeneScan software
(Perkin-Elmer). To determine the signiﬁcance of the spec-
tratype data, 3 separate B6-control spectratype experiments
(each using 2-3 mice) were performed to obtain a mean ± SD
for the area represented by each peak of each Vβ spectratype.
Experimental spectratypes were considered significantly
skewed if a dominant peak exceeded the mean of control B6
mice by >4 SD (P ≤ .025).
In Vivo Analysis for GVL Potential and GVHD
Syngeneic (B6 → B6) and allogeneic (B6 → B6D2)
BMTs were performed to determine the antileukemia poten-
tial of Vβ-enriched T-cell populations. B6 recipients, lethally
irradiated with 9.5 Gy (136 cGy/min) from a 137Cs source
(Mark-1 Model 68 gamma irradiator; J.L. Shephard, San
Fernando, CA) and B6D2 recipients, lethally irradiated with
split-dose 13 Gy, were injected 4 to 6 hours later with a B6
donor inoculum of 2 × 106 naive ATBM cells alone or in
combination with various numbers of MMB3.19-primed
T-cell populations. Donor T cells were either unfraction-
ated, enriched for the CD4+ subset, or enriched for selected
Vβ-expressing T cells and were from mice that had been
presensitized 2 to 3 weeks earlier with irradiated (40 Gy)
MMB3.19 cells (5 × 106, intraperitoneally [IP]). Recipients
were challenged 1 day later with MMB3.19 cells (7.5 × 104 or
2 × 104, IP in PBS). Mice were monitored daily for morbidity
and mortality and weighed 2 times per week until the termi-
nation of experiments. Median survival times (MSTs) were
calculated, and the nonparametric Wilcoxon 2-sample rank
test was used for statistical comparisons of survival curves.
RESULTS
Representation of V Families in MMB3.19-Primed
Donor T-Cell Populations
In previous studies using the MMB3.19 myeloid
leukemia model, it was demonstrated that MMB3.19-
primed donor CD4+ or unfractionated T cells were capable
of mediating potent in vivo GVL responses following syn-
geneic B6 → B6 bone marrow transplantation [17,27,35].
The ﬁrst step in the current investigation, therefore, was to
analyze the TCR Vβ representation of the T-cell repertoire
in the leukemia-primed donor mice. CD4+ or CD8+ T cells
were harvested from either naive or MMB3.19-primed mice
and ﬂow cytometric analysis was performed using available
Vβ-specific MoAbs. This analysis revealed that, although
the representation of different Vβ families varied widely
within subsets (from 1% to 18% of the total CD4+ or CD8+
populations), there were no obvious differences in the rela-
tive representation of Vβ families in naive mice compared
with MMB3.19-primed mice (Figure 1A and B). This ﬁnding
Figure 1. Flow cytometric analyses of donor MMB3.19-primed or
naive CD4+ and CD8+ T cells. Donor CD4+ and CD8+ populations
were isolated from either naive B6 mice ( ) or from mice presensitized
2 weeks prior with irradiated (40 Gy) MMB3.19 ( ). Cells were
stained with appropriate ﬂuorescein isothiocyanate (FITC)-labeled Vβ-
speciﬁc monoclonal antibodies (MoAbs). Results are displayed as per-
centage of total CD4+ (A) or CD8+ (B) T cells and represent data of
pooled cells from 5 mice for each group.
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suggests that any expansion of leukemia-reactive clonotypes
did not signiﬁcantly alter the overall percentage of the cor-
responding Vβ families.
TCR CDR3-Size Spectratype Analysis of Leukemia-
Reactive and Alloreactive T-Cell Populations
Because leukemia-specific responses are possible in
autologous and syngeneic transplantation [40-43] and in
allogeneic transplantation without overt GVHD [44], an
experimental system was used whereby tumor reactivity
and alloreactivity could be clearly differentiated without
the confounding effects of alloantigens expressed on
tumor cells. To this end, studies were conducted in both a
syngeneic antileukemia system (B6 anti-MMB3.19) and a
haploidentical transplantation system [B6(H2b) →
B6D2(H2b/d)]. To specifically identify leukemia-reactive
and alloreactive subpopulations of CD4+ and CD8+ T cells,
TCR CDR3-size spectratype analyses were performed on
MMB3.19-primed LN or splenic T cells from B6D2 trans-
plantation recipients and compared with control naive-B6
T-cell spectratypes. Both leukemia-primed and alloreactive
CD4+ and CD8+ T-cell populations exhibited oligoclonal
responses, with both unique and overlapping Vβ family
involvement (Table). In the CD4+ anti-MMB3.19 response,
unique expansions (relative to the alloreactive response)
were detected in the Vβ2, 7, 13, and 15 families. In the
CD8+ response, which was more heterogeneous than the
CD4+ pattern, unique expansions were observed in the
Vβ4, 6, 7, 8, 10, 12, and 15 families.
Using a Syngeneic BMT Model to Investigate GVL
Potential of Leukemia-Reactive V Families 
To determine whether CDR3-size spectratyping could
identify antileukemia populations of T cells capable of
mediating an in vivo GVL effect, we administered selected
Vβ families of unfractionated (containing both CD4+ and
CD8+) B6 T cells based on the anti-MMB3.19 tumor-skew-
ing proﬁles. The Vβ7+ T-cell family was chosen because it
exhibited highly skewed spectratypes for both CD4+ and
CD8+ T-cell subsets (Figure 2D and E). In addition, Vβ11+
and Vβ13+ families were chosen based on their skewed pro-
files in CD8+ and CD4+ T-cell populations, respectively
(Figure 2A and B). Administration of B6 ATBM and 1 × 106
MMB3.19-primed Vβ7,11,13-enriched T cells to irradiated
B6 recipients conferred potent GVL responses with 88%
long-term survivors (MST, >44 days; P ≤ .01) compared
with the early fatality of control MMB3.19-challenged mice
receiving only ATBM cells (MST, 21 days; Figure 3). This
level of protection was not signiﬁcantly different (P > .30)
from that observed in a group receiving an equivalent num-
ber (1 × 106) of unfractionated MMB3.19-primed B6
T cells, which demonstrates that the protective GVL effect
could be mediated by a population of T cells enriched
(>70%) for the Vβ7+,11+,13+ families. A repeat experiment
using half the number of Vβ7,11,13-enriched T cells (5 ×
105) similarly provided long-term GVL activity (80% sur-
vival of >58 days compared to 60% receiving equal num-
bers of unfractionated MMB3.19-primed T cells; P > .66;
data not shown).
To more speciﬁcally address the GVL potential of indi-
vidual Vβ families, 2 of the B6 CD4+ Vβ families that
exhibited highly skewed antileukemia spectratypes, Vβ7
and Vβ13 (Figure 2B and D), were each selected for trans-
plantation into syngeneic recipients. Upon MMB3.19
leukemia challenge, B6 recipients of B6 ATBM alone or
with 2 × 105 Vβ13-enriched (>60%) CD4+ T cells displayed
similar mortality rates (MST, 17.5 or 18 days for groups
receiving ATBM alone or with Vβ13-enriched CD4+
T cells; P ≥ .65) (Figure 4A) and, therefore, failed to display
any effective GVL response. In contrast, transfer of 1 × 105
Vβ7-enriched (>50%) B6 CD4+ T cells significantly
extended survival (MST, 22 days) of MMB3.19-challenged
recipients compared with those receiving ATBM alone or
in combination with 1 × 105 Vβ7-depleted B6 CD4+ T cells
(P ≤ .05). An inoculum of 2 × 106 unfractionated MMB3.19-
primed CD4+ T cells (equivalent to a CD4+ T-cell popula-
tion that would contain at least 5 × 104 Vβ7+ cells) was used
as a reference point for the GVL effect and provided a mar-
ginally better GVL response (MST, 24 days versus 22 days
for the Vβ7+ group; P > 0.05) than that observed in recipi-
ents of the Vβ7-enriched CD4+ T cells. These results sug-
gest that there are other GVL participants in addition to
the Vβ7+ population, but the Vβ7+ responders certainly
formed an important component of the CD4-mediated
GVL response. Hypothetically, the Vβ13+ population could
still be involved in the antileukemia response by, for exam-
ple, contributing to the level of essential inflammatory
cytokines, even though on their own they were ineffectual
mediators of GVL activity.
Summary of T-Cell Receptor Vβ Complementarity-Determining Region
3–Size Spectratype Analyses*
B6 anti-B6D2 B6 anti-MMB3.19
V Family CD4+ CD8+ CD4+ CD8+
1 – – – +/–
2 – + + –
3 +/– + – +/–
4 +/– – NS +
5 + – – –
6 – – – +
7 +/–† – + +
8 + +/– + +
9 NS + NS +
10 + +/– + +
11 – + +/– +
12 + – – +
13 +/– + + –
14 + + + +
15 – +/– + +
16 + – +/– –
18 – + – +
20 – – NS –
*All spectratype experiments were performed twice. + indicates
significantly skewed band(s) were detected compared with a control
naive C57BL/6 (B6) T-cell population; –, no skewed bands; +/–, skew-
ing of band(s) in 1 experiment but not the other; NS, no spectratype
was observed in either experiment.
†Skewed band in B6 anti-(B6×DBA/2)F1 (B6D2) Vβ7 CD4+ was
different from that in B6 anti-MMB3.19 Vβ7 CD4+ spectratype.
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Separation of GVL Effects From GVH Effects in an
Allogeneic BMT Model Using Leukemia-Reactive 
V Families
After it was demonstrated that CDR3-size spectratyping
could identify anti-MMB3.19 leukemia populations of T cells
that can mediate in vivo GVL effects in syngeneic recipi-
ents, the next important step was to test the hypothesis that
selective administration of these tumor-reactive Vβ families
in a semiallogeneic situation could allow development of
GVL responses with minimal induction of GVHD. To
approach this experimentally, 2 T-cell Vβ families (Vβ6 and
Vβ7) were selected by spectratyping on the basis of their
detected antileukemia reactivity without overt B6 anti-
B6D2 (H2b/d) alloreactivity in either the CD4 or CD8 sub-
sets (Table). In addition, in the case of the Vβ7 population,
the GVL potential in the syngeneic model, described above,
had already been demonstrated (Figure 4B). It was also
hypothesized that optimum activity of the Vβ6+CD8 T-cell
antitumor population, detected by the spectratype analysis,
would be enhanced by the presence of CD4-derived help.
Positively-selected Vβ6+7+ cells (7 × 105 cells) from
MMB3.19-primed B6 mice were transferred along with
ATBM to lethally irradiated haploidentical B6D2 mice that
were subsequently challenged with MMB3.19 cells. Recipi-
ents of Vβ6,7-enriched (80%) T cells exhibited signiﬁcantly
prolonged survival times (P < .05) over those receiving an
equal number of MMB3.19-primed unfractionated T cells
(Figure 5A). It is important to note that because a sublethal
dose of donor T cells was used, there were no deaths in cor-
responding groups that were not challenged with the
MMB3.19 leukemia. Therefore, mortality was due either to
leukemia burden alone or to a combination of leukemia and
GVH effects, but not to GVHD alone. Weight loss was the
parameter used to determine the severity of GVHD in those
groups that did not receive MMB3.19. B6D2 recipients of
Vβ6,7-enriched T cells experienced signiﬁcantly less weight
loss than those receiving the unfractionated T cells (P < .05
from day 35 onward), although some disease effects were
still evident in comparison with the ATBM control group
(Figure 5B). These data indicate that selective administra-
tion of leukemia-reactive Vβ families can provide a signiﬁ-
cant GVL effect while decreasing the severity of GVHD.
To further reduce GVHD, the GVL potential of B6 Vβ7+
CD4+ T cells alone was investigated in the semiallogeneic
Figure 2. Selected histograms of T-cell receptor complementarity-determining region 3 (CDR3)-size spectratype analyses of CD4+ and CD8+
T-cell populations. Histograms of Vβ11+ CD8+ (A) and Vβ13+ CD4+ (B) T cells from naive or MMB3.19-presensitized mice with signiﬁcant skew-
ing (arrow) in the latter populations. C, Histograms of Vβ10+ CD4+ T cells from naive or MMB3.19-presensitized mice as an example of a statisti-
cally, but not obviously, skewed Vβ family (arrow). Histograms of Vβ7+ CD4+ (D) and CD8+ (E) T cells from naive C57BL/6 (B6), transplant-
receiving B6D2, or MMB3.19-presensitized B6 mice with significant skewing (arrow) in the leukemia-primed population, but not in the B6
anti-B6D2 population. F, Histograms of Vβ5+ CD8+ T cells demonstrating no signiﬁcant skewing in either leukemia-primed or alloreactive T cells.
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transplantation setting. To enhance potential GVL effects,
the recipient mice were challenged with a lower dosage of
2 × 104 MMB3.19 cells. Leukemia-challenged B6D2 recipi-
ents of 2.5 × 105 MMB3.19-primed Vβ7-enriched (82%)
CD4+ T cells exhibited signiﬁcantly extended survival times
(MST, 66 days) compared with recipients of ATBM alone or
of unfractionated MMB3.19-primed CD4+ T cells (both
with MST of <33 days; P < .05) (Figure 6A). An important
observation was that B6D2 recipients of Vβ7+-enriched
CD4+ T cells experienced little, if any, weight loss compared
with recipients of ATBM alone (Figure 6B). In contrast,
recipients of 2.5 × 105 unfractionated CD4+ donor T cells
experienced a detectable level of GVHD, as evidenced by
signiﬁcant weight loss (P < .05 from day 25 onward, except
for day 40) (Figure 6B). These results support the hypothe-
sis that selective administration of leukemia-reactive Vβ
families can provide a signiﬁcant GVL effect without corre-
sponding GVHD.
DISCUSSION
Using both syngeneic and semiallogeneic murine HSCT
models, we have found that transplantation of donor
leukemia-reactive T-cell subpopulations, identiﬁed by TCR
Vβ CDR3-size spectratyping, can provide potent GVL
effects. An important result was that in the semiallogeneic
model this GVL effect coincided with the lack of signiﬁcant
antihost GVHD development. To clarify our tumor model
system, in a semiallogeneic haploidentical situation of either
P → F1 (a → a × b haplotypes) or (a × b) → (a × c) combina-
tions (most representative of parent → child clinical trans-
plantations), donor cells will be capable of recognizing the
host alloantigens expressed by the incompatible MHC mole-
cules on the tumor cells, as well as tumor-speciﬁc antigens
presented on compatible syngeneic MHC molecules shared
by the donor. We selected our model as the optimum one to
clearly address the hypothesis of whether these syngeneic
antitumor responses can be selected for, based on Vβ spec-
tratype analysis, while avoiding the alloreactive responses. We
chose the B6 → (B6D2)F1 model because it avoids the com-
plication of marrow rejection and allows us to focus only on
the alloreactive antihost and antitumor responses. In this
model, we challenged with the B6-origin MMB3.19 leukemia
cells, which were completely syngeneic to the donor. We used
this cell type because a myeloid tumor of the F1 type did not
exist and because we wanted to focus on the “true” antitumor
antigen response, uncomplicated by the potential alloreactive
component against the tumor cells. Theoretically, the Vβ
repertoire approach will not work in a completely allogeneic
transplantation situation, because allogeneic donor cells
Figure 3. Vβ7,11,13-enriched donor T cells provide a graft-versus-
leukemia effect in a syngeneic bone marrow transplantation model.
Lethally irradiated (9.5 Gy) B6 mice received 2 × 106 B6 anti-Thy-1
monoclonal antibody–treated (T cell–depleted) bone marrow (ATBM)
cells and either 1 × 106 unfractionated MMB3.19-primed B6 T cells or
1 × 106 Vβ7,11,13-enriched (>70%) T cells. Aside from an ATBM
control group, all mice were challenged on day 1 with 7.5 × 104
MMB3.19 cells administered intraperitoneally and monitored for sur-
vival. For all groups, n = 5, except for the group receiving Vβ7+11+13+
T cells (n = 8). A repeat experiment using half the number of T cells
yielded similar results.
Figure 4. Vβ7-enriched CD4+ T cells, but not Vβ13+ CD4+ T cells,
provide a graft-versus-leukemia (GVL) effect in a syngeneic bone mar-
row transplantation model. Lethally irradiated (9.5 Gy) B6 mice were
injected with 2 × 106 anti-Thy-1 monoclonal antibody–treated (T cell–
depleted) bone marrow (ATBM) cells and MMB3.19-primed CD4+
T cells that were either (A) Vβ13-enriched (60%; 2 × 105) or (B) Vβ7-
enriched (>50%; 1 × 105). As a reference point for GVL activity, 2 × 106
unfractionated MMB3.19-primed CD4+ T cells were also administered
in each experiment. Aside from an ATBM control group, all mice were
challenged on day 1 with 7.5 × 104 MMB3.19 cells administered
intraperitoneally and monitored for survival. Results are representative
of 2 similar experiments using Vβ13-enriched CD4+ T cells and 3 simi-
lar experiments using various doses of Vβ7-enriched CD4+ T cells.
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would be able to recognize only alloantigens (incompatible
MHC) on the tumor cells. Thus, we believe that the semiallo-
geneic model system is the most suitable for addressing the
potential of the Vβ family GVL selection approach.
TCR Vβ CDR3-size spectratyping has been used to ana-
lyze and track immune responses to known antigens [45-47]
as well as unknown antigens [28,33,34,48]. Because Vβ spec-
tratyping allows for identiﬁcation of responding T-cell pop-
ulations without intimate knowledge of the target antigens,
it has potential clinical application, especially in the area of
HSCT for leukemia. Selecting dominant tumor-reactive Vβ
families from donor T cell–subset populations may allow for
an effective GVL response while decreasing the risk of
severe GVHD development. Operationally, alloreactive
responses often generate heterogeneous Vβ family involve-
ment, as exempliﬁed in the B6 anti-B6D2 response (Table),
in which two thirds of all Vβ families tested exhibited skew-
ing for the entire T-cell population. However, this response
repertoire is narrowed when one focuses on individual CD4+
and CD8+ T-cell subsets, in which only about one third of
the repertoire was skewed in either case. This more limited
Vβ family involvement leaves a greater window for ﬁnding
unique antileukemia Vβ family responses within the subsets.
In the clinical setting, these unique antileukemia Vβ
responses could potentially be exploited by using selection
techniques (depending upon availability of Vβ-specific
MoAbs) to provide these potential GVL responding cells in
conjunction with HSCT, either at the time of initial trans-
plant or as delayed infusions.
There is extensive controversy over whether clinical
GVL responses can actually be separated from GVHD
alloreactivity directed to either MHC or minor histocom-
patibility host antigens. Several studies support the argu-
ment that a signiﬁcant portion of the GVL response is due
to alloreactivity [49-54]. On the other hand, leukemia-spe-
cific responses are possible, as demonstrated by in vitro
cytotoxic T-lymphocyte studies targeting proteinase 3 [32]
and bcr-abl junctional peptides [29-31] and by observations
of GVL effects in autologous and syngeneic transplantations
Figure 5. Vβ6,7-enriched T cells mediate a graft-versus-leukemia
effect with minimization of graft-versus-host disease (GVHD) in an
allogeneic bone marrow transplantation (BMT) model. Lethally irradi-
ated B6D2 mice were injected with 2 × 106 B6 106 anti-Thy-1 monoclo-
nal antibody–treated (T cell–depleted) bone marrow (ATBM) cells and
either 7 × 105 MMB3.19-primed Vβ6,7-enriched (80%) T cells or an
equal number of unfractionated T cells. A, Survival curves for groups
receiving MMB3.19 challenge (7.5 × 104; intraperitoneally) 1 day post-
BMT. B, Percentage of initial body weight for groups not receiving
leukemia challenge and therefore GVHD-associated. For all groups,
n = 5, and the results are representative of 2 similar experiments.
Figure 6. Vβ7-enriched CD4+ T cells mediate a graft-versus-leukemia
response with minimal graft-versus-host disease (GVHD) induction in
an allogeneic bone marrow transplantation (BMT) model. Lethally
irradiated B6D2 mice were injected with 2 × 106 B6 anti-Thy-1 mono-
clonal antibody–treated (T cell–depleted) bone marrow (ATBM) cells
and 2.5 × 105 MMB3.19-primed Vβ7-enriched (82%) B6 CD4+ T cells
or an equal number of unfractionated CD4+ T cells. A, Survival curves
for groups receiving MMB3.19 challenge (2 × 104 cells administered
intraperitoneally) 1 day post-BMT. B, Percentage of initial body
weight for groups not receiving leukemia challenge and indicative of
GVHD. Groups contained 4 to 8 mice and were representative of
results from 2 similar experiments.
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[41-43]. Certainly, the availability of leukemia-speciﬁc anti-
gens will vary depending on the type and stage of the tumor
involved, the individual patient’s MHC molecules required
for presentation, and the repertoire of the donor’s respond-
ing T cells. However, the potential for assessing leukemia-
speciﬁc responses, if they can be induced, is afforded by Vβ
spectratype analysis, even without prior knowledge of the
antigens involved. Importantly, Jiang et al. [55] have identi-
fied leukemia-specific T-cell clones that show different
preferential Vβ usage than do clones reactive to autologous
phytohemagglutinin blasts, suggesting that leukemia-speciﬁc
populations may be separable by Vβ expression.
In the allogeneic transplants using leukemia-reactive
Vβ6,7-enriched T cells (Figure 5), there was still a detectable
level of GVHD indicated by comparative weight loss. This
activity could be due either to residual contaminating allore-
active cells (from other Vβ families) or to the possibility that
the CDR3-spectratype analysis did not detect low-level
alloreactivity within the Vβ6 and 7 families. Regarding the
purity of the donor cell preparations, it was technically difﬁ-
cult to achieve a high level of purity of Vβ families that nor-
mally represented a small percentage of the overall initial T-cell
population. For example, Vβ13+ CD4+ T cells represented
about 1% to 2% of the total CD4+ population (Figure 1), so
enrichment to 60% to 70% of the population (Figure 4A) was
considered to be substantial. However, such a level of purity
still allows for the possibility of contaminating alloreactive
cells in the transplant, and there is certainly room for
improvement in this approach. Nevertheless, the absolute
number of potentially alloreactive cells is diminished in these
leukemia-reactive Vβ-enriched cell preparations in relation to
those containing unfractionated T cells and would be
expected to result in a correspondingly lower level of GVHD.
Importantly, administration of a single leukemia-reactive Vβ
family of CD4+ T cells eliminated detectable GVHD (Fig-
ure 6B), indicating that this method of identification and
enrichment of leukemia-reactive populations could effectively
lead to GVL activity without GVHD.
Many issues will have to be addressed for this identiﬁca-
tion and separation approach to be effective in a clinical set-
ting. One of these issues is the availability of MoAbs speciﬁc
for many of the human Vβ regions. These antibodies must be
developed before the Vβ enrichment process can be optimally
performed. Another important clinical consideration relates to
potential increased graft failure of selected Vβ-enriched donor
populations, if administered at the time of HSCT. This prob-
lem may be obviated by more intensive preconditioning
regimens or by increased numbers of donor stem cells. Alter-
natively, the use of Vβ-selected populations could be reserved
for the donor-lymphocyte infusion (DLI) setting, so that
engraftment would not be an issue at that time. Another clini-
cally related obstacle involves procurement of leukemia
samples before debulking treatments are initiated. Potential
recipients would have to be selected early in a treatment pro-
tocol to obtain tumor samples for in vitro restimulation exper-
iments. In addition, in vitro restimulation of potential
antileukemia populations will require deﬁning the optimal in
vitro conditions needed to identify and expand those donor
T-cell populations that demonstrate a preferential anti-
leukemia response. Furthermore, if long-term culturing is
required, decreased reactivity of long-term T-cell cultures will
have to be addressed. Although each of these obstacles will
require signiﬁcant effort to address, each is ultimately solvable.
Because the approach we describe here requires identiﬁ-
cation of leukemia-reactive and alloreactive Vβ families by
spectratype analysis, it would be particularly well-suited clin-
ically in a DLI setting, as mentioned above. The time lapse
between initial stem cell transplantation and DLI would
allow for identiﬁcation, selection, and possibly expansion of
leukemia-restricted donor T cells. Such an approach should
enhance the beneﬁts of DLI, permitting a beneﬁcial GVL
effect while reducing the incidence and severity of GVHD.
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